Icahn School of Medicine Myeloid Malignancy Workshop 2025

Date & Location Friday, March 21, 2025, 7:00 AM – 6:00 PM, Leon & Norma Hess Center for Science and Medicine, Davis Auditorium, 1470 Madison Avenue, New York, NY
Target Audience Specialties – Academic/Research, Genomic Medicine, Geriatric Medicine, Hematology, Internal Medicine, Multiple Specialties, Nurse Practitioner, Nursing, Oncology, Pathology, Pharmacist, Physician Assistant

Course Overview
This workshop will include speakers with international recognition for excellence in science and clinical care of myeloid malignancies. Given the relative rarity of each disease, rapid pace of scientific discovery over the last several years, recent approval of novel agents, and the multitude of investigational agents in late-stage clinical development it is imperative to provide cutting edge updates in a focused manner. The target audience for this CME-accredited event will include clinical and laboratory-based physicians, trainees, laboratory investigators, pharmacists, nurses, nurse practitioners, physician assistants, and patients. The event would take place in a lecture hall on the campus of Mount Sinai. The talks will be 30 minutes in duration and followed by 10-minute question and answer sessions. The event will be moderated by John Mascarenhas, Marina Kremyanskaya and Ruben Mesa and the audience will be encouraged to participate in Q&A sessions. Additionally, there will be audience response system (ARS) questions before and after to gauge impact on learning.
Objectives

Understand modern laboratory tools for exploring myeloid malignancy pathway for therapeutic targeting
Recognize the appropriate evidence-based therapies for patients with myeloid leukemia
Understand complex cellular mechanisms driving thrombosis in myeloproliferative neoplasms
Identify patient specific approaches and therapeutic options for patients with myelodysplastic syndromes
Discuss the emerging results of laboratory and clinical studies providing insights into biology and potential interventions in CHIP/CCUS
Identify treatment goals for systemic mastocytosis that incorporate next generation kit inhibitors.

The Icahn School of Medicine’s Myeloid Malignancy Workshop 2025 is best for hematologists, oncologists, clinician-scientists, fellows, and researchers focused on myeloid cancers who want cutting-edge updates on diagnostics, therapeutics, and clinical trials.
Who Should Attend

Hematologists and oncologists treating patients with AML, MDS, MPNs, and other myeloid malignancies
Fellows and residents specializing in hematology-oncology or internal medicine
Clinical researchers and translational scientists working on novel therapies and molecular targets
Pharmaceutical professionals involved in drug development for hematologic cancers
Advanced practice providers and oncology nurses supporting myeloid cancer care

What You’ll Learn
This workshop delivers focused, high-level insights into the rapidly evolving landscape of myeloid malignancies. Key highlights include:

Updates on newly approved agents and investigational therapies in late-stage development
Advances in molecular diagnostics, risk stratification, and personalized treatment
Multidisciplinary perspectives from internationally recognized experts in clinical care and research
Discussions on clinical trial design, patient selection, and outcome optimization
Networking opportunities with leaders in academic and industry settings

+ Topics:
Friday, March 21, 2025

7:45AM – 8:45AM Registration and Breakfast
8:45AM – 9:00AM Introduction John Mascarenhas, MD Marina Kremyanskaya, MD Ruben A. Mesa, MD
9:00AM – 9:40AM Recent Insights into Myeloid Malignancy and Clonal Hematopoiesis from Human iPSC Models Eirini Papapetrou, MD, PhD
9:40AM – 10:20AM CHIP and CCUS Next Steps Kelly Bolton, MD
10:20AM – 11:00AM State of the Art Management for Systemic Mastocytosis Jason Gotlib, MD, MS
11:00AM – 11:30AM Break
11:30AM – 12:10PM Modeling Thrombosis in MPN Joan D Beckman, MD
12:10PM – 12:50PM Novel Approaches and Approvals in MDS Guillermo Garcia-Manero, MD
12:50PM – 1:50PM Lunch
1:50PM – 2:30PM Evolving Paradigm Shifts in CML Jorge Cortes, MD
2:30PM – 3:10PM Deciphering Esoinophilia Amy Klion, MD
3:10PM – 3:30PM Break
3:30PM – 4:10PM Future Directions in AML Therapy Naval Daver, MD
4:10PM – 4:50PM Insights from the Hematopathologist Daniel A. Arber, MD
4:50PM – 5:15PM Awards Presentation and Closing Remarks John Mascarenhas, MD Marina Kremyanskaya, MD Ruben A. Mesa, MD
5:15PM – 5:17PM Adjourn